

Targeted Mutation Panel in NSCLC: A Single Center Experience

Meena A. Pangarkar¹, Kosu Badlani², Suruchi Aggarwal³, Anand Pathak⁴

How to cite this article:

Meena A. Pangarkar, Kosu Badlani, Suruchi Aggarwal *et al.* Targeted Mutation Panel in NSCLC: A Single Center Experience. *Ind J Canc Educ Res* 2024;12(2):57-62.

Abstract

Introduction: Non Small Cell Lung Carcinoma (NSCLC) is one of the top ranking cancers in both males and female patients across India. Majority of cases are in advanced stage at presentation.

Recent advances in molecular techniques and drug discovery have made the mutation analysis of this carcinoma a part of standard investigation before treatment in NSCLC. In view of cost constraints, a targeted gene panel test is advised for all cases. The purpose of this study is to document the application of this practice at a single tertiary cancer care center in central India.

Material and Methods: Two hundred and thirty one cases of NSCLC were reported at our hospital from January 2019 till December 2023. Triage testing was done initially for Epidermal growth factor receptor (*EGFR*) gene mutations by ARMS RT-PCR/ Targeted NGS. Subsequently *EGFR* negative cases were tested for Analysis of Anaplastic lymphoma receptor tyrosine kinase gene (*ALK*), Repressor of Silencing 1 (*ROS1*) gene by immunohistochemistry (IHC).

Results: 106 cases were found to have tested positive for these mutations, 56 were males and 50 were females. The average age for male patients was 60.17 yrs and for female patients was 56.3 yrs.

EGFR mutations were found in 40.69% cases, out of which exon 19 deletion and exon 21 L858R were the most frequent (38.09%).

Rare cases of single and compound mutations were also seen.

ALK and *ROS1* gene rearrangements were found in 4.76% and 0.43% respectively.

EGFR, *ALK* and *ROS1* mutations were mutually exclusive.

Conclusion: Targeted gene mutation testing is a very significant investigation in patients with advanced NSCLC, as it results in tailoring and optimising the treatment for individual patients and offers hope for the best outcome.

Keywords: Mutation test, Lung carcinoma, *EGFR*, *ALK*, *ROS1*.

Author's Affiliation: ¹Head of Department, ²Research Fellow, ³Medical Director, Department of Laboratory Medicine, National Cancer Institute, Jamtha, Nagpur 441108, Maharashtra, India. ⁴Head Scientific affairs, Narayana Health city, 258/A, Bommasandra, Hosur road, Bengaluru, 560100, India

Corresponding Author: Meena Pangarkar, Head of Department, Department of Laboratory Medicine, National Cancer Institute, Jamtha, Nagpur 441108, Maharashtra, India.

E-mail: meenapangarkar@gmail.com

Received on: 24-05-2024

Accepted on: 14-08-2024



This work is licensed under a Creative Commons
Attribution-NonCommercial-ShareAlike 4.0.

INTRODUCTION

Lung Cancer is one of the top ranking cancers in Indian population.¹

Non Squamous Cell Lung Carcinoma (NSCLC) is the most frequent type of Lung Carcinoma found in India.^{2,3} The majority of patients usually present in advanced clinical stage, with metastatic disease. Amongst the NSCLC, adenocarcinoma is the most frequent subtype, followed by Squamous cell carcinoma, Large cell Carcinoma and Adenosquamous carcinoma.

Since the availability and proven superiority of targeted therapy over standard chemotherapy, molecular testing has become the standard of care for patients of advanced NSCLC. As the cost of testing for all mutations by WES /WGS is still significantly high, clinical practice relies on testing for a targeted panel of the most frequently found somatic mutations by RT PCR/ IHC technique.

Many studies from India have found that *EGFR*, *ALK* and *ROS1* are the most frequently found mutations in Indian patients.⁴⁻⁸

EGFR-Epidermal Growth Factor Receptor (*EGFR*) is a cellular transmembrane receptor protein. The activation of *EGFR* plays an important role in cellular tumor growth proliferation and metastasis spread. *EGFR* tyrosine kinase (TK) gene mutations have been identified in non-small cell lung cancer (NSCLC) cases.⁹

Patients who test positive for these mutations, when treated with appropriate oral tyrosine kinase inhibitors (TKIs-eg: Gefitinib or Erlotinib) show improved and durable outcomes alongwith lesser toxicity and better quality of life as compared to patients on conventional chemotherapy.¹⁰⁻¹²

ALK: Genomic rearrangements in *ALK* can drive aberrant proliferation and tumorigenesis in several cancers including non-small cell lung cancer (NSCLC). Literature suggests, 3-7% of *ALK* fusions are observed in lung cancers.¹³ As per the NCCN guidelines, presence of this fusion confers sensitivity to first and second generation *ALK* tyrosine kinase inhibitors (*ALK* TKIs): Crizotinib, Ceritinib, Alectinib, Brigatinib.¹⁴

ROS1: *ROS1* gene rearrangements are reported in 1-2% lung adenocarcinomas and are associated with response to multitargeted TKI Crizotinib.

Both *ALK* and *ROS1* rearrangements are detected by FISH, however immunohistochemistry (IHC) is an alternate screening modality with high

sensitivity and specificity.¹⁵ IHC results are reported as H Score. Because gene rearrangements are rare, sensitive IHC screening is reasonable before ISH.

This study reports the occurrence of *EGFR*, *ALK* and *ROS1* mutations in patients of NSCLC from central India for the first time.

MATERIAL AND METHODS

Patient selection and Testing process: This is a retrospective observational study in patients tested for five years, from January 2019 to December 2023.

The tumor tissue samples of 231 advanced NSCLC patients were tested for mutations in *EGFR*, *ALK* and *ROS1* genes.

The 221/231 samples were in the form of Formalin fixed paraffin embedded (FFPE) tumor tissue blocks and the other 10 were peripheral blood collected in Streck tubes (liquid biopsy).

Considering the cost of genetic testing, triaging was done by performing the *EGFR* mutation test first, if it came positive, no further testing was done. If the *EGFR* mutation test was negative, *ALK* and *ROS1* mutation testing was performed.

EGFR mutation test by PCR: DNA extracted from the tissue block sample was tested for the presence of hotspot mutations (Exon 19 deletion/insertion, Exon 20 insertions and substitution mutations- G719X, S768I, T790M, C797S and Exon 21 mutations L858R and L861Q in the *EGFR* gene) using ARMS real-time PCR. The target exons were amplified with mutation specific primers. Mutations were reported according to HGVS guidelines for mutation nomenclature (www.hgvs.org) and according to the reference sequence NM_005228.³

Liquid Biopsy Next Generation Sequencing: In case the tumor tissue failed the qualitative criteria for PCR test, peripheral blood sample in Streck tube was collected and circulation free DNA (cf DNA) was extracted. Lung cancer liquid biopsy panel was used to detect genomic alterations (SNVs, InDels, & Fusions) in 24 lung cancer related actionable genes including *EGFR*, *ALK* and *ROS-1*. cfDNA isolated from blood plasma was used to perform UMI-based target enrichment and sequencing using a custom capture kit. The QC passed libraries were sequenced to a minimum depth >20000X (pre-UMI) on validated Illumina sequencing platform and compressed to >2000X (post-UMI) for variant analysis. The sequences obtained were aligned to human reference genome (GRCh38/hg38)

using BWA program.^{16,17} Somatic mutations were identified using UMI corrected Senton pipeline.¹⁸ Only non-synonymous and splice site variants found in the coding regions of the genes* of interest were used for clinical interpretation. The mutations were annotated using in-house annotation pipeline (VariMAT).

The sequenced reads were pre-processed and aligned to the reference human genome (Genome Version: hg38). Gene fusions were detected by multiple programs with and without UMI-aware algorithms. The cutoff and parameters of the algorithms and pipelines were finetuned based on our validation samples. Reportable alterations were prioritized, classified, and reported based on AMP-ASCO-CAP guidelines.¹⁹

Immunohistochemistry (IHC): If the *EGFR* mutations were not found in the sample through PCR, further testing for *ALK* and *ROS1* fusion was done by IHC. The IHC was performed using Roche-Ventana Benchmark GX slide autostainer with primary antibody clone D5F3 for *ALK* and CellSignal D4D6 rabbit mAb for *ROS1*. the secondary reagents used were Optiview DAB with amplification.

RESULTS

A total of 231 samples from patients of non small cell lung cancer (NSCLC) were tested for mutational analysis in the *EGFR*, *ALK* and *ROS1* genes. Of these 221 were Formal in fixed paraffin embedded tumor tissue blocks and 10 were peripheral blood samples (cf DNA). The cohort included 145 male patients and 86 female patients with ages ranging from 28-86 years. The mean age was 60.17 years for males and 56.30 years for females.

The most common NSCLC subtypes in both sexes were adenocarcinoma, followed by squamous cell carcinoma, large cell carcinoma and adenosquamous carcinoma. (Table 1)

Table 1: Subtypes of NSCLC in present study

NSCLC	M	F	Total
Adenocarcinoma	135	81	216
Squamous cell carcinoma	8	4	12
Large cell carcinoma	2	0	2
Adenosquamous carcinoma	1	0	1
Total	146	85	231

Mutational Analysis, revealed that actionable mutations were present in 45.88% of all cases. Specifically, *EGFR* mutations were found in 40.69% of cases, *ALK* rearrangements in 4.76% and *ROS1* rearrangement in 0.43%. (Table 2).

Table 2: Mutations found in NSCLC in present study

Mutations	M	F	Percentage	Total
EGFR	49	45	40.69	94
ALK	7	4	4.76	11
ROS-1	0	1	0.43	1
Total	56	50	45.88	106

Among the *EGFR* mutations, the most frequent were exon 19 deletions (58 cases), followed by exon 21 L858R mutations (30 cases). Less common mutations included exon 20 insertions (2 cases) and exon 18 mutations (2 cases). Additionally, one patient had coexistent exon 18 and 21 mutations and another had coexistent exon 19 deletion and 20 insertion mutations. (Table 3)

Table 3: Types of *EGFR* mutations found in present study

Type of <i>EGFR</i> mutation	M	F	Total
exon 19 deletion	33	25	58
exon 21 L858R	15	15	30
exon 20 Ins	1	1	2
exon 18	1	1	2
exon 18 and 21	0	1	1
exon 19 del and 20 Ins	1	0	1
Total	51	43	94

The majority of exon 19 deletions were observed in adenocarcinomas with 32 cases in males, and 24 in females alongwith one case each in squamous cell carcinoma.

Similarly, most exon 21 L858R mutations were in adenocarcinomas with 14 cases in males, and 14 cases in females and one case each in squamous and adenosquamous carcinoma. Single and compound uncommon mutations were also predominantly seen in adenocarcinoma.

DISCUSSION

This study describes the mutational profile of 231 patients of NSCLC from a single tertiary cancer care center in Central India.

In the present study, mutations were detected in 106 (45.88%) patients. Out of these, *EGFR* mutations were the most frequent (40.69%), followed by *ALK* (4.76%). *ROS1* mutation was found in only one case. These findings are comparable with the study conducted by Deka *et al.*, Kishore *et al.* and Kesri *et al.*^{4,6,7} (Table 4)

Table 4: Comparison of *EGFR*, *ALK* and *ROS1* mutations in different studies

Name of Study	EGFR mutations	ALK mutations	ROS1 mutations
Present study	45.88%	4.76%	0.43%
Deka <i>et al.</i>	56.14%	33.33%	4.54%
Kishore <i>et al.</i>	37.23%	5.23%	3.85%
Kesri <i>et al.</i>	29.89%	4.6%	1.14%

A meta-analysis of 26 different studies by Raman *et al.*⁵ states that there is a wide range of frequency of these three mutations across different regions of India. (*EGFR* 11.9-51.8%, *ALK* 4.1-21.4%, *ROS1* 3.5-4.1%).

The mutation frequency in the other Asian countries as reported by Shi *et al.* (50.2%) in China, 47.2% in Hong Kong, 52.3% in the Philippines, 62.1% in Taiwan, 53.8% in Thailand and 64.2% in Vietnam.²⁰

The *EGFR* test by RT PCR is designed to detect mutations in exon 18,19,20, and 21 of the *EGFR* gene. In the present study, the frequency of single common mutations (exon 19 del/exon 21 L858R) was 93.61%. Most of the cases had exon 19 mutation, of which exon 19 deletion mutation was the commonest one found in 61.70% of patients. Second most common mutation was L858R mutation on exon 21 found in 31.91% of cases. This finding is comparable to Singh *et al.*²¹ who found the frequency of common single mutations (exon 19 del/ exon 21 L858R) to be 79.5%.

Both these mutations are associated with responsiveness to *EGFR* tyrosine kinase inhibitors: Gefitinib, Erlotinib and Afatinib.^{22,23} Dacomitinib and Osimertinib are also approved as a first line treatment in these cases, and have shown to reduce the progression risk by 54% as compared to standard Tyrosine kinase inhibitor therapy.²⁴

A single uncommon mutation in the present study was Exon 20 insertion (2 cases). The frequency of exon 20 mutations in the various Indian studies varied from 2.8% to 25.39%. Exon 20 mutations confer resistance to the classical TKI therapy that is given in cases which harbor *EGFR* mutations; thus, the detection of exon 20 mutation is therapeutically

significant.²⁵⁻²⁷ Despite initial challenges in targeting *EGFR* exon 20 insertions, over the past 5-10 years a number of emergent therapies and clinical trials have been specifically developed for this unique molecular subgroup. Amivantanab has been granted FDA approval in 2021.²⁸

Uncommon and compound *EGFR* mutations have been described by Indian authors²¹ and also were found in the present study.

Exon 18 mutation was seen in 2 cases while one case each with compound mutations (exon 18 and 21) and (exon 19 deletion and 20 insertion) were found in the present study. The appropriate treatment for such patients has not been clarified.²⁹

ALK gene rearrangements were the next frequently occurring mutations (4.76%) in the present study, and are comparable to Kishore *et al.* (5.23%)⁶ and Kesri *et al.* (4.6%).⁸ One study by Deka *et al.* showed a much higher frequency (33.33%).⁴

ROS1 gene rearrangements are quite rare in various studies across India,^{4,6,8} and the present study also had only one case.

EGFR, *ALK* and *ROS1* mutations were seen to be mutually exclusive.

CONCLUSION

NSCLC cases across India show a wide range in the occurrence of actionable and druggable mutations.

The two most common mutations found in 88 patients of NSCLC in the present study were in the *EGFR* gene-exon 19 deletion and exon 21 L858R mutation. All these patients were eligible for treatment with the standard tyrosine kinase inhibitors (TKIs).

Two patients were found to have exon 20 insertion mutation in the *EGFR* gene and since this mutation confers resistance to the usual tyrosine kinase inhibitors, they were not suited for targeted therapy.

Eleven patients were found to have mutations in the *ALK* gene, and were eligible to receive *ALK* TKIs.

Only a single patient had mutation in the *ROS1* gene which made the patient eligible for multitargeted TKIs.

Targeted gene Mutation testing is a very significant investigation in patients with advanced NSCLC, as it results in tailoring and optimising the treatment for individual patients and offers hope for the best outcome.

LIMITATION

All the patients in the present study are on clinical follow up, however the Progression free survival and Overall survival remains to be compared between the two groups of mutation positive and mutation negative cases. This comparison will reflect the difference between the clinical outcomes of these two groups.

REFERENCES

1. Navneet Singh, Sushma Agrawal, Sabita Jiwnani, Divya Khosla, Prabhat S. Malik, Anant Mohan, Prasanth Penumadu, Kuruswamy Thurai Prasad. Lung Cancer in India, Journal of Thoracic Oncology, Volume 16, Issue 8, 2021, Pages 1250-1266.
2. Mohan A, Garg A, Gupta A, Sahu S, Choudhari C, Vashistha V, Ansari A, Pandey R, Bhalla AS, Madan K, Hadda V. Clinical profile of lung cancer in North India: A 10-year analysis of 1862 patients from a tertiary care center. Lung India. 2020 May 1;37(3):190-7.
3. Kaur H, Sehgal IS, Bal A, Gupta N, Behera D, Das A, Singh N. Evolving epidemiology of lung cancer in India: Reducing non-small cell lung cancer-not otherwise specified and quantifying tobacco smoke exposure are the key. Indian journal of cancer. 2017 Jan 1;54(1):285-90.
4. Deka H, Mahanta N, Kalita NK, Goswami BC. Mutational Profiling by Next-Generation Sequencing in Patients with Metastatic Non-Small Cell Lung Carcinoma: Our Experience. South Asian Journal of Cancer. 2024 Apr 23.
5. Raman R, Ramamohan V, Rathore A, Jain D, Mohan A, Vashistha V. Prevalence of highly actionable mutations among Indian patients with advanced non-small cell lung cancer: A systematic review and meta-analysis. Asia-Pacific Journal of Clinical Oncology. 2023 Feb;19(1):158-71.
6. Kishore RR, Pan V. Correlation between ALK, ROS1 Biomarkers and EGFR Oncogene Mutations in Lung Tumours: Our Observations in an Apex Oncopathology Laboratory. Asian Pacific Journal of Cancer Biology. 2023 May 7;8(2):111-7.
7. Thomas R, Balamurugan G, Varayathu H, Ghorpade SN, Kowsik PV, Dharman B, Thomas BE, Ramaswamy V, Nanjiah T, Patil S, Naik R. Molecular epidemiology and clinical characteristics of epidermal growth factor receptor mutations in NSCLC: A single-center experience from India. Journal of Cancer Research and Therapeutics. 2023 Jul 19.
8. Kesri R, Goyal H, Gupta G, Bharti D, Sharma R. Prevalence and Clinicopathologic Risk Factors for Epidermal Growth Factor Receptor, Anaplastic Lymphoma Kinase, and ROS-1 Fusion in Metastatic Non-small Cell Lung Carcinoma. Journal of Radiation and Cancer Research. 2022 Apr 1;13(2):48-53.
9. Pao, W. and Miller, V.A. (2005) Epidermal growth factor receptor mutations, small molecule kinase inhibitors, and non-smallcell lung cancer: current knowledge and future directions. J. Clin. Oncol. 23, 2556
10. Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, Mariotto AB, Lowy DR, Feuer EJ. The effect of advances in lung-cancer treatment on population mortality. New England Journal of Medicine. 2020 Aug 13;383(7):640-9.
11. Sequist, L.V., *et al.* (2008) First-line gefitinib in patients with advanced non-small cell lung cancer harboring8 somatic EGFR mutations. J. Clin. Oncol. 15, 2442.
12. Porta, R. *et al.* (2008) Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV nonsmall-cell lung cancer (NSCLC) patients (p). J. Clin. Oncol. 26(May 20 suppl), abstr 8038.
13. Pillai RN, Ramalingam SS. The biology and clinical features of non-small cell lung cancers with EML4-ALK translocation. Current Oncology Reports. 2012 Apr;14(2):105-110.
14. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012 Oct;13(10):1011-9.
15. Sholl LM, Sun H, Butaney M, Zhang C, Lee C, Jänne PA, Rodig SJ. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol. 2013 Sep;37(9):1441-9. doi: 10.1097/PAS.0b013e3182960fa7.
16. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009 Jul 15;25(14):1754-60.
17. Meyer LR, Zweig AS, Hinrichs AS, Karolchik D, Kuhn RM, Wong M, Sloan CA, Rosenbloom KR, Roe G, Rhead B, Raney BJ, Pohl A, Malladi VS, Li CH, Lee BT, Learned K, Kirkup V, Hsu F, Heitner S, Harte RA, Haussler M, Guruvadoo L, Goldman M, Giardine BM, Fujita PA, Dreszer TR, Diekhans M, Cline MS, Clawson H, Barber GP, Haussler D, Kent WJ. The UCSC Genome Browser database: extensions and updates 2013. Nucleic Acids Res. 2013 Jan;41(Database issue):D64-9.
18. Kendig KI, Baheti S, Bockol MA, Drucker TM, Hart SN, Heldenbrand JR, Hernaez M, Hudson ME, Kalmbach MT, Klee EW, Mattson NR, Ross

- CA, Taschuk M, Wieben ED, Wiepert M, Wildman DE, Mainzer LS. Sentieon DNASeq Variant Calling Workflow Demonstrates Strong Computational Performance and Accuracy. *Front Genet.* 2019 Aug 20;10:736.
19. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, Nikiforova MN. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. *J Mol Diagn.* 2017 Jan;19(1):4-23.
 20. Shi Y, Li J, Zhang S, Wang M, Yang S, Li N, *et al.* Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology-Mainland China subset analysis of the Pioneer study. *PLoS One* 2015;10:e0143515.
 21. Singh V, Nambirajan A, Malik PS, Thulkar S, Pandey RM, Luthra K, Arava S, Ray R, Mohan A, Jain D. Spectrum of uncommon and compound epidermal growth factor receptor mutations in non-small-cell lung carcinomas with treatment response and outcome analysis: A study from India. *Lung Cancer.* 2020 Nov;149:53-60.
 22. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med.* 2004 May 20;350(21):2129-39.
 23. Dungo RT, Keating GM. Afatinib: first global approval. *Drugs.* 2013 Sep;73(13):1503-15.
 24. Cheng Y, He Y, Li W, Zhang HL, Zhou Q, Wang B, Liu C, Walding A, Saggese M, Huang X, Fan M, Wang J, Ramalingam SS. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. *Target Oncol.* 2021 Mar;16(2):165-176.
 25. Noronha V, Prabhash K, Thavamani A, Chougule A, Purandare N, Joshi A, *et al.* EGFR mutations in Indian lung cancer patients: Clinical correlation and outcome to EGFR targeted therapy. *PLoS One* 2013;8:e61561.
 26. Chougule A, Prabhash K, Noronha V, Joshi A, Thavamani A, Chandrani P, *et al.* Frequency of EGFR mutations in 907 lung adenocarcinoma patients of Indian ethnicity. *PLoS One* 2013;8:e76164.
 27. Doval DC, Azam S, Batra U, Choudhury KD, Talwar V, Gupta SK, *et al.* Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study. *J Carcinog* 2013;12:12.
 28. Meador CB, Sequist LV, Piotrowska Z. Targeting EGFR Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates. *Cancer Discov.* 2021 Sep;11(9):2145-2157.
 29. Xu H, Yang G, Li W, Li J, Hao X, Xing P, Yang Y, Wang Y. EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes. *Front Oncol.* 2021 Sep 2;11:713483.

